BioCentury
ARTICLE | Company News

Progenics cancer, infectious, gastrointestinal news

October 1, 2012 7:00 AM UTC

For the second time in 13 months, Progenics restructured and will focus on its cancer pipeline. The company reduced headcount by 27 (26%) to 77. The move comes after the company received a July complete response letter from FDA for an sNDA for subcutaneous Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in patients with non-cancer pain (see BioCentury, Aug. 6). ...